The latest price target for Can Fite Biopharma (AMEX:CANF) was reported by D. Boral Capital on December 17, 2025. The analyst firm set a price target for $4.00 expecting CANF to fall to within 12 months (a possible NaN% downside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Can Fite Biopharma (AMEX:CANF) was provided by D. Boral Capital, and Can Fite Biopharma maintained their buy rating.

There is no last upgrade for Can Fite Biopharma

There is no last downgrade for Can Fite Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Can Fite Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Can Fite Biopharma was filed on December 17, 2025 so you should expect the next rating to be made available sometime around December 17, 2026.

While ratings are subjective and will change, the latest Can Fite Biopharma (CANF) rating was a maintained with a price target of $11.00 to $4.00. The current price Can Fite Biopharma (CANF) is trading at is $undefined, which is out of the analyst’s predicted range.